Collin is an experienced leader with a strong track record of building high-functioning teams and executing clinical programs within contract research organizations (CROs) as well as large and small biopharmaceutical companies. He is driven to streamline the clinical development process for life science companies and to remove the cost-inefficiencies which have contributed to the exorbitant price of promising therapies. He has extensive Phase I-IV experience over a range of therapeutic areas with a specialization in oncology, including targeted small-molecules and cutting-edge immunotherapy.
Collin has overseen projects from pre-IND to NDA submission and subsequent regulatory inspections for Sponsor companies and he is intimately familiar with the challenges Sponsor companies face along this path. Those challenges are the reason he founded Highline Sciences with a mission to improve the status quo for all stakeholders involved in drug development.
Collin has a BA in Biology from the University of Kansas and earned his MBA from the Haas School of Business at the University of California, Berkeley.